Tiziana Life Sciences Ltd (TLSA) Stock Price, Quote & News

Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: www.tizianalifesciences.com

Address:

14/15 Conduit Street, London, United Kingdom

rp6577 Jun. 11 at 5:53 AM

$TLSA the first Alzheimer’s patient was dosed on 17 December 2025. That means we could get some initial data any time from 17 June 2026. Could be a nice bump before the main event of the SPMS data in September/October. Should get some further MSA updates in relation to the remaining 8 patients as well. A packed schedule of catalysts $XBI

1 · Reply

Iceman89 Jun. 10 at 6:11 PM

$TLSA sorry for the drop, i had to sell 40k shares on my trading account to buy options in another short-term opportunity today. Abysmal liquidity... Have a nice summer ⛱️ 🌞

0 · Reply

rp6577 Jun. 10 at 12:56 PM

$TLSA https://www.nasdaq.com/market-activity/stocks/tlsa/short-interest Some short interest out there at the moment. Quite high days to cover as well. Some positive news and shorts could be scrambling

0 · Reply

Housatonic1864 Jun. 9 at 2:41 PM

$TLSA is there footage of the Jeffrey’s Global Healthcare Conference?

0 · Reply

Airforcecaptain Jun. 9 at 6:41 AM

$TLSA If the Europeans approve Tolebrutinib, what will happen to Foralumab? https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-24-10-09-46-3280641

2 · Reply

mrnobody617 Jun. 8 at 8:13 PM

$LYFT $TLSA $UBER Future $AVAV Customers? https://seekingalpha.com/news/4601533-aerovironment-expands-deployment-of-connected-vehicle-traffic-information-platform

0 · Reply

JuggernautRaider Jun. 8 at 1:47 PM

$TLSA and $CGTX form a nice long term neuroscience duo. Who’s my third? If you tell me $BIIB then i’ll block you. I want my four horsemen of cognitive therapeutics baby 🧠 💥 🚀 Buying more $TNXP from the car 🚘

0 · Reply

kellymone2 Jun. 8 at 12:28 PM

$TLSA watching this closely 👀

0 · Reply

JuggernautRaider Jun. 6 at 8:54 AM

$TNXP i bought shares on this week’s dip - did you @Proposition_Joe ? 😉 How about my buddy @alphaonetrading ? 🏦 @Hoppanin check in - how many shares are you holding? This right here is the Tonixphile retail collective. I have many ideas and little time - I am a Father first. But, man… i have seen what martin shkreli did to my industry (biopharma), and what I am doing is the exact opposite ☯️ I keep telling you all… I am an expert in this space because of 20+ years of hard work going back to my college days at Northwestern 📕 Then again maybe i am just a big dumb 2 meter tall former college football player 💪 $CGTX and $TLSA are also on my radar. Who else has a juicy pick like $EYPT @Duediligence20 ? 🚀

20 · Reply

rp6577 Jun. 5 at 4:04 PM

$TLSA you want to own this stock going into SPMS data in September/October. CEO confirmed several big pharma have asked to see the data first. Following the Sanofi phase 3 failure, Tiziana is out front. Can see a bidding war following data. Expecting a strong partnership announcement, all potentially a buy out. Remember that SPMS is only one indication. There are several others, including Alzheimer’s which is massive. This is now a platform and will be valued as such Excited is understatement $XBI $SNY $LABU

0 · Reply

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

2026-05-21T15:05:09.000Z - 21 days ago

Tiziana fully enrolls Phase 2 placebo-controlled MS trial

May 21, 2026, 11:00 AM EDT - 21 days ago

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

2026-05-19T12:13:28.000Z - 23 days ago

Tiziana Life Sciences announces updated intranasal foralumab data

May 19, 2026, 7:00 AM EDT - 23 days ago

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

2026-05-14T13:46:05.000Z - 4 weeks ago

Tiziana Phase 2 trial for foralumab shows reduced brain inflammation

May 14, 2026, 7:00 AM EDT - 4 weeks ago

Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

2026-04-16T12:01:24.000Z - 2 months ago

Tiziana Life announces publication of preclinical data in bioRxiv preprint

Apr 16, 2026, 7:00 AM EDT - 2 months ago

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

Apr 14, 2026, 7:00 AM EDT - 2 months ago

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

Apr 1, 2026, 7:00 AM EDT - 2 months ago

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

2026-02-25T12:25:15.000Z - 3 months ago

Tiziana Life Sciences announces new data on nasal foralumab

Feb 25, 2026, 7:00 AM EST - 3 months ago

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

2026-01-20T16:20:10.000Z - 5 months ago

Tiziana Life Sciences announces publication of intranasal foralumab results

Jan 20, 2026, 11:15 AM EST - 5 months ago

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

Jan 16, 2026, 2:45 PM EST - 5 months ago

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

2026-01-16T12:05:16.000Z - 5 months ago

Tiziana Life Sciences prices 6.4M shares at $1.25 in registered direct offering

Jan 16, 2026, 7:00 AM EST - 5 months ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

Jan 9, 2026, 7:00 AM EST - 5 months ago

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

2025-12-29T13:15:44.000Z - 5 months ago

Tiziana Life Sciences files annual safety report for intranasal foralumab

Dec 29, 2025, 8:00 AM EST - 5 months ago

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

2025-12-19T16:05:39.000Z - 6 months ago

Tiziana Life Sciences Chairman raises stake to 36% with acquisition of shares

Dec 19, 2025, 11:00 AM EST - 6 months ago

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

Dec 17, 2025, 10:00 AM EST - 6 months ago

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

2025-12-17T13:50:17.000Z - 6 months ago

Tiziana Life Sciences doses first patient in Phase 2 Alzheimer’s trial

Dec 17, 2025, 8:45 AM EST - 6 months ago

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial

2025-12-15T20:15:08.000Z - 6 months ago

Tiziana Life Sciences CEO Ivor Elrifi purchases 163,400 shares

Dec 15, 2025, 3:07 PM EST - 6 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

2025-12-15T12:35:32.000Z - 6 months ago

Tiziana Life Sciences announces withdrawal of proposed public offering

Dec 15, 2025, 7:30 AM EST - 6 months ago

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

2025-12-12T19:15:11.000Z - 6 months ago

Tiziana Life Sciences to dose first patient in Phase 2 Alzheimer’s trial

Dec 12, 2025, 2:10 PM EST - 6 months ago

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial

2025-12-02T12:05:39.000Z - 6 months ago

Tiziana Life Sciences plans to spinout IL-6 asset into separate listed company

Dec 2, 2025, 7:00 AM EST - 6 months ago

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

2025-11-25T13:40:48.000Z - 7 months ago

Tiziana Life announces Phase 2 foralumab study accepted into Healey ALS program

Nov 25, 2025, 8:30 AM EST - 7 months ago

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

Nov 13, 2025, 8:30 AM EST - 7 months ago

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

2025-10-29T11:22:32.000Z - 8 months ago

Tiziana Life Sciences to present at BIO-Europe in Vienna

Oct 29, 2025, 7:00 AM EDT - 8 months ago

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Sep 30, 2025, 8:30 AM EDT - 9 months ago

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

2025-09-25T12:35:22.000Z - 9 months ago

Tiziana Life Sciences to advance TZLS-501 monoclonal antibody

2025-09-24T12:40:39.000Z - 9 months ago

Tiziana Life announces poster presentation on intranasal foralumab trial

Sep 24, 2025, 8:30 AM EDT - 9 months ago

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

2025-09-15T12:05:13.000Z - 9 months ago

Tiziana Life Sciences announces U.S. DoD awarded research grant to study SCI

Sep 15, 2025, 8:00 AM EDT - 9 months ago

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Sep 5, 2025, 8:30 AM EDT - 9 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Aug 14, 2025, 8:30 AM EDT - 10 months ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Aug 11, 2025, 9:00 AM EDT - 10 months ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Jul 21, 2025, 7:00 AM EDT - 11 months ago

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Jun 13, 2025, 10:30 AM EDT - 1 year ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Jun 13, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences to Present at the Bio International Convention

May 23, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 15, 2025, 8:00 AM EDT - 1 year ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 9, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 6, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Mar 4, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Feb 27, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Feb 21, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Feb 18, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Feb 11, 2025, 9:15 AM EST - 1 year ago

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease

Jan 23, 2025, 3:00 PM EST - 1 year ago

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Jan 23, 2025, 8:54 AM EST - 1 year ago

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

Jan 22, 2025, 4:05 PM EST - 1 year ago

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

rp6577 Jun. 11 at 5:53 AM

1 · Reply

Iceman89 Jun. 10 at 6:11 PM

$TLSA sorry for the drop, i had to sell 40k shares on my trading account to buy options in another short-term opportunity today. Abysmal liquidity... Have a nice summer ⛱️ 🌞

0 · Reply

rp6577 Jun. 10 at 12:56 PM

0 · Reply

Housatonic1864 Jun. 9 at 2:41 PM

$TLSA is there footage of the Jeffrey’s Global Healthcare Conference?

0 · Reply

Airforcecaptain Jun. 9 at 6:41 AM

$TLSA If the Europeans approve Tolebrutinib, what will happen to Foralumab? https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-24-10-09-46-3280641

2 · Reply

mrnobody617 Jun. 8 at 8:13 PM

$LYFT $TLSA $UBER Future $AVAV Customers? https://seekingalpha.com/news/4601533-aerovironment-expands-deployment-of-connected-vehicle-traffic-information-platform

0 · Reply

JuggernautRaider Jun. 8 at 1:47 PM

0 · Reply

kellymone2 Jun. 8 at 12:28 PM

$TLSA watching this closely 👀

0 · Reply

JuggernautRaider Jun. 6 at 8:54 AM

20 · Reply

rp6577 Jun. 5 at 4:04 PM

0 · Reply

JuggernautRaider Jun. 5 at 8:18 AM

Me too 🤷‍♂️ I apologize again if you think I would ever violate anyone’s privacy. That’s not me at all But, much like I share information i could make a fortune off of… if it is shared on stocktwits then it is wide open 🌎 $TNXP $IMRX $CCCC and $TLSA

1 · Reply

rispi Jun. 3 at 7:51 PM

$TLSA ohhhh boy…. Diluition in track

1 · Reply

SKYROCKETMAN Jun. 3 at 6:34 PM

$AAPL $TLSA will fly into

0 · Reply

WHATABOUTSTOCKS Jun. 3 at 6:23 PM

$TLSA reminder ;)

0 · Reply

JuggernautRaider Jun. 3 at 5:58 PM

$CGTX in for a small taste, loving cognition therapeutics 🧠 Pair it with $TLSA or another budding biotech in that space 🤔

0 · Reply

rp6577 Jun. 3 at 5:53 PM

$TLSA added on that dip at 1.17. Bargain given what we have coming up

0 · Reply

StockBoySam Jun. 3 at 3:32 PM

$TLSA Signs are promising, and hopefully optimistic.

0 · Reply

Housatonic1864 Jun. 2 at 4:01 PM

$TLSA all of the naysayers will be shocked earnings

1 · Reply

WebwallXii Jun. 2 at 4:48 AM

$RDW $ASTS $RKLB $NVDA $TLSA god bless my bull family ♥️

1 · Reply

WebwallXii Jun. 1 at 10:56 PM

$RDW $ASTS $RKLB $NVDA $TLSA 🚀 SpaceX IPO = once‑in‑a‑lifetime catalyst. Not just an IPO — the moment the entire space sector goes FULL PUBLIC 🌌💥 AI 🤖 + Quantum ⚛️ + Space 🚀 = the next‑decade power trio. And we’re STILL early. RDW at $20 🔥 ASTS at $105 🚀 CHEAP. AS. HELL. Both hold first‑mover advantages in orbital infrastructure 🛰️ and space‑to‑cell connectivity 📡 — impossible for legacy giants to copy overnight. Tiny caps. Massive runway. Fuse ready to ignite when SpaceX goes public. This isn’t “someday.” This is buy → hold → let your portfolio transform 💰✨

0 · Reply

rp6577 Jun. 1 at 8:21 PM

$TLSA watching this again and it makes you very excited to get to September and the SPMS data. Multiple Pharma wanting to be first in line to see the data. What that means is that they will be competing with each other. A deal is going to get done as a result. Whether it’s a partnership or a buyout. Big Pharma are going to want Foralumab in their portfolio. $XBI $LABU $SNY

1 · Reply

WHATABOUTSTOCKS Jun. 1 at 8:10 PM

$TLSA reminder ;)

0 · Reply

Market Cap	155.26M
Revenue (ttm)	0.00
Net Income (ttm)	-18.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	279,181
Avg Vol	206,202
Day's Range	N/A - N/A
Shares Out	127.26M
Stochastic %K	20%
Beta	0.44
Analysts	Strong Sell
Price Target	$9.00